Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 21-25 of 25 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepointBranford, S.; Ross, D.; Yeung, D.; Braley, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)
2010Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trialYeung, D.; Osborn, M.; White, D.; Branford, S.; Haswell, L.; Slader, C.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.; Forsyth, C.; Ross, D.; Mills, A.; Grigg, A.; Hughes, T.; Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2020Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionPagani, I.; Dang, P.; Saunders, V.; Grose, R.; Shanmuganathan, N.; Kok, C.; Carne, L.; Rwodzi, Z.; Watts, S.; McLean, J.; Braley, J.; Altamura, H.; Yeung, D.; Branford, S.; Yong, A.; White, D.; Hughes, T.; Ross, D.
2019Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibKok, C.; Yeung, D.; Lu, L.; Watkins, D.; Leclercq, T.; Dang, P.; Saunders, V.; Reynolds, J.; White, D.; Hughes, T.
2013PCR-mediated recombination can lead to artificial chimera formation, which may pose as BCR-ABL1 compound mutationsParker, W.; Phillis, S.; Yeung, D.; Hughes, T.; Scott, H.; Branford, S.; 55th American Society of Hematology Annual Meeting and Exhibition (07 Dec 2013 - 10 Dec 2013 : New Orleans, Louisiana)